Exact Sciences Corp. and Thrive Earlier Detection Corp. entered into a definitive agreement under which Exact Sciences will acquire Thrive.
This author has yet to write their bio.
Meanwhile lets just say that we are proud raincastle contributed a whooping 9 entries.
Foghorn Therapeutics announced the pricing of its initial public offering of 7.50 million shares of its common stock.
C4 Therapeutics priced its upsized initial public offering at $19 per share for gross proceeds of $182.4 million.
Clinical-stage biopharmaceutical company announced the pricing of its IPO of 5.8 million shares of common stock.
Clinical-stage precision medicine company announced the closing of its IPO of 23 million shares of its common stock.
Genetic medicines company announced the closing of its initial public offering of 12,105,263 shares of common stock.
Cullinan Oncology announced Series B funding of $98.5 million, adding financial backing from institutional investors and family offices.
Gene editing biotech Beam Therapeutics raised $180 million in its IPO after offering 48% more shares than anticipated.
Black Diamond Therapeutics Inc. more than doubled in its trading debut after raising $201 million in an IPO that exceeded its goals.